Intech Investment Management LLC Makes New $175,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Intech Investment Management LLC purchased a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,275 shares of the company’s stock, valued at approximately $175,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Amalgamated Bank lifted its holdings in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after acquiring an additional 2,402 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Neumora Therapeutics by 35.0% during the third quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after purchasing an additional 6,900 shares during the period. Quarry LP bought a new position in shares of Neumora Therapeutics during the 2nd quarter valued at about $98,000. Ballentine Partners LLC bought a new position in shares of Neumora Therapeutics during the 3rd quarter valued at about $178,000. Finally, SkyOak Wealth LLC acquired a new position in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $147,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Insider Buying and Selling

In other news, insider Robert A. Lenz sold 30,788 shares of Neumora Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now owns 339,205 shares of the company’s stock, valued at $4,006,011.05. This trade represents a 8.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at $342,303. This represents a 41.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,400 shares of company stock worth $686,361. Corporate insiders own 26.40% of the company’s stock.

Neumora Therapeutics Stock Up 6.5 %

Shares of NMRA stock opened at $10.29 on Friday. The firm has a market cap of $1.66 billion, a PE ratio of -5.50 and a beta of 3.34. Neumora Therapeutics, Inc. has a 12 month low of $8.33 and a 12 month high of $21.00. The company’s fifty day simple moving average is $12.42 and its 200-day simple moving average is $11.45.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the previous year, the company earned ($1.14) EPS. On average, equities analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on NMRA shares. Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research note on Friday, November 22nd. Finally, JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.